Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Grace Therapeutics, Inc. (GRCE) vs Werewolf Therapeutics, Inc. (HOWL)

Grace Therapeutics, Inc. and Werewolf Therapeutics, Inc. are both Biotechnology companies. Grace Therapeutics, Inc. and Werewolf Therapeutics, Inc. are of similar size ($47.7M and $45.4M). Grace Therapeutics, Inc. grew revenue faster over the last twelve months: 1,286.8% against −5.21%. Grace Therapeutics, Inc. has the higher net margin (0.00% vs −141.9%) and the lower return on invested capital (−43.4% vs 0.00%). Across the 16 metrics below, Grace Therapeutics, Inc. leads on 11 and Werewolf Therapeutics, Inc. on 5.

Valuation

Metric GRCE HOWL Biotechnology median
P/E n/m n/m 7.88
P/S 183.34 1.91 11.47
P/B 0.76 2.86 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m n/m 0.74
EV/Sales 116.74 1.90 10.73
Earnings yield (55.66%) (76.04%) (28.84%)
Free cash flow yield (27.88%) (64.04%) (23.03%)

Profitability

Metric GRCE HOWL Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (128.18%) 0.00%
Net margin 0.00% (141.94%) 0.00%
Free cash flow margin 0.00% (122.51%) 0.00%
Return on equity (36.19%) (119.86%) (57.72%)
Return on assets (33.74%) (59.31%) (49.22%)
Return on invested capital (43.36%) 0.00% 0.00%

Growth

Metric GRCE HOWL Biotechnology median
Revenue growth (TTM) 1,286.81% (5.21%) 5.64%
EPS growth (last fiscal year) 40.51% 18.40% —
Revenue growth, 5-year CAGR (22.91%) — 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GRCE HOWL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.47 2.91 4.73
Net debt to EBITDA 1.53 0.97 0.96

Dividend

Metric GRCE HOWL Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric GRCE HOWL Biotechnology median
Market cap 45.44m 47.68m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack